Abstract
Although striking evidence exists that argues for the usefulness of hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis (PC), many aspects of this therapy have yet to be standardized. As interest in this modality increases, there are several avenues of research to be explored. How important is the cytoreductive effort, the temperature elevation increment, and the length of time for the hyperthermic perfusion? We review what is known and what may be explored in the near future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409–422.
Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 1998;78:1479–1487.
Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A gynecologic oncology group study. J Clin Oncol 2003;21:3194–3200.
Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69(2):235–241.
Ohno S, Streble FR, Stephen LC, et al. Haemotological toxicity of carboplatin and cisplatin with whole body hyperthermia in rats. Br J Cancer 1993;68(3):469–474.
Stellar M, Egorin M, Trimble EL, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with smallvolume residual ovarian cancer. Cancer Chemother Pharmacol 1999;43(2):106–114.
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.
Rietbroek RC, Katschinski DM, Reijers MH, et al. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia 1997;13(5):525–533.
Mohamed F, Marchettini P, Stuart OA, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003;10(4):463–468.
Bissery MC, Guenard D, Sueritte-Vogelein F. Experimental anti-tumor activity of taxotere, a taxol analogue. Cancer Res 1991;51:4845–4852.
Hill BT, Whelan RDS, Shelland SA. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Investig New Drugs 1994;12:169–182.
Mohamed F, Stuart OA, Glehen O, et al. Docetaxel and hyperthermia: Factors that modify thermal enhancement. J Surg Oncol 2004;88(1):14–20.
De Bree E, Romanos J, Michalakis J, et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 2003;23:3019–3027.
Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299–303.
Rietbroek RC, van de Vaart PJM, Haveman J, et al. Hyperthermia enhances the cytotoxicity and platinum DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997;123:6–12.
Elias D, Sideris L, Pocard M, et al. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol 2004;15:781–785.
Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001;37(8):979–984.
Hofstra LS, Bos AM, de Vries EJ, et al. A phase I and pharmacokinetic study of intraperitoneal topotecan. Br J Cancer 2001;85(11):1627–1633.
Ning S, Macleod K, Abra RM. Hyperthermia induces doxorubicin release from longcirculating liposomes and enhances their anti-tumor effect. Int J Radiat Oncol Biol Phys 1994;29(4):827–834.
Ben-Yosef R, Gipps M, Zeira M. Hyperthermia and liposomal encapsulated doxorubicin. Isr Med Assoc J 2003;5(6):407–409.
Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model. Cancer Res 2000;60(5):1197–1201.
Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: Pharmacokinetics, tissue distribution and tolerance. Ann Oncol 2004;15:1558–1565.
Hahn DM. Potential for therapy of drugs with hyperthermia. Cancer Res 1979;39:2264–2268.
Reinhold HS, Endrich B. Tumour microcirculation as a target for hyperthermia. Int J Hyperthermia 1986;2:111–137.
Raaphorst GP. Fundamental aspects of hyperthermic biology. In: Field SB, Hand JW, eds. An Introduction to the Practical Aspects of Clinical Hyperthermia. London: Taylor and Francis; 1990:10–54.
Van der Zee J. Heating the patient: A promising approach? Ann Oncol 2002;13:1173–1184.
Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001;17(1):1–18.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Richard, S., Edwards, R.P. (2007). Future Directions in the Delivery of Hyperthermic Intraperitoneal Chemotherapy. In: Helm, C.W., Edwards, R.P. (eds) Intraperitoneal Cancer Therapy. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-195-6_12
Download citation
DOI: https://doi.org/10.1007/978-1-59745-195-6_12
Publisher Name: Humana Press
Print ISBN: 978-1-58829-878-2
Online ISBN: 978-1-59745-195-6
eBook Packages: MedicineMedicine (R0)